Current Approaches in Breast Cancer Treatment

Year 2022, Volume: 42 Issue: 1, 46 - 59, 01.03.2022

Pelin İrem Sert Zekiye Tuba Tüylü Küçükkılınç

https://doi.org/10.52794/hujpharm.959879

Cited By: 1

Abstract

Cancer is the most common type of cancer in women. Many genetic and environmental factors play an important role in breast cancer and therefore it is considered as a heterogeneous disease. Nowadays, new treatment approaches are being studied for reasons such as the different treatment responses of the defined subtypes to each other, the development of resistance to traditional therapies in clinical use, the high rate of relapse after treatment, and the damage to healthy cells by the chemotherapeutics. Current approaches in breast cancer treatment such as immunotherapy, PI3K / AKT / mTOR inhibitors, JAK / STAT inhibitors, CDK4 / 6 inhibitors target signaling pathways that play a role in breast cancer development and / or contribute to the development of resistance

Keywords

Breast cancer, drug resistance, signal pathway, inhibitor, new treatment approaches

Meme Kanseri Tedavisindeki Güncel Yaklaşımlar

Abstract

Meme Kanseri kadınlarda en sık görülen kanser tipidir. Meme kanserinde pek çok genetik ve çevresel faktörler rol oynamaktadır ve bu nedenle heterojen bir hastalık olarak değerlendirilmektedir. Tanımlanmış olan alt tiplerinin tedaviye verdikleri yanıtın birbirlerinden farklı olması, klinik kullanımda yer alan geleneksel tedavilere karşı direnç gelişmesi, tedaviden sonra nüks oranlarının yüksek olması, kullanılan kemoterapötiklerin aynı zamanda sağlıklı hücrelere de zarar vermesi gibi nedenlerle günümüzde yeni tedavi yaklaşımları üzerinde çalışılmaktadır. Meme kanseri tedavisindeki immünoterapi, PI3K/Akt/mTOR inhibitörleri, JAK/STAT inhibitörleri, CDK4/6 inhibitörleri gibi güncel yaklaşımlar meme kanseri gelişimde rol oynayan ve/veya direnç gelişimine katkıda bulunan sinyal yolaklarını hedef almaktadır.

Keywords

Meme kanseri, ilaç direnci, sinyal yolağı, inhibitörler, yeni tedavi yaklaşımları

References

• Referans1. Siegel RL, Miller KD, Jemal A: Cancer Statistics. Cancer Journal for Clinicians 2020, 70(1):7-30.
• Referans 2. McPherson K, Steel CM, Dixon JM: Breast cancer—epidemiology, risk factors, and genetics. British Medical Journal 2000, 321(7261):624–628.
• Referans 3. Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J: Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone ReceptorPositive Advanced Breast Cancer. Clinical Cancer Research 2018, 24(18):4380–4387.
• Referans 4. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB: Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology 2013, 31(17):2128-2135.
• Referans 5. O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS: A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment 2018, 170(3):547-557.
• Referans 6. Godone RLN, Leitao GM, Araújo NB, Castelletti CHM, Lima-Filho JL: Clinical and molecular aspects of breast cancer: Targets and therapies. Biomedicine & Pharmacotherapy 2018, 106:14-34.
• Referans 7. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA: Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clinical Cancer Research 2013, 19(19):5505-5512.
• Referans 8. Eroles P, Bosch A, Pérez-Fidalgo JA, Ana Lluch: Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews 2012, 38:698–707.
• Referans 9. Allison KH: Molecular pathology of breast cancer: what a pathologist needs to know. American Journal of Clinical Pathology 2012, 138(6):770-780.
• Referans 10. Rivenbark AG, O'Connor S, Coleman WB: Molecular and Cellular Heterogeneity in Breast Cancer Challenges for Personalized Medicine. The American Journal of Pathology 2013, 183(4):1113-1124.
• Referans 11. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji Xiaojuan, Liu W, Huang B, Luo W, Liu B, Lei Y, Du S, Vuppalapati A, Luu HH, Haydon RC, He T, Ren G: Breast cancer development and progression:Risk factors, cancer stem cells, signaling,pathways, genomics, and molecular,pathogenesis. Genes & Diseases 2018, 5(2):77-106.
• Referans 12. Polack K: Breast cancer: origins and evolution. Journal of Clinical Investigation 2007, 117(11):3155-3163.
• Referans 13. Burgess AW: EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008, 26(5):263-274.
• Referans 14. Daniele L, Sapino A: Anti-HER2 treatment and breast cancer: state of the art,recent patents, and new strategies. Recent Patents on Anticancer Drug Discovery 2009, 4(1):9-18.
• Referans 15. Hennessy BT, Smith D, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005, 4(12):988-1004.